Atherosclerosis refers to situation when fatty substance deposits in the arteries and leads to its clogging. The fatty deposition in the arteries is known as plaque. The plaques are made up of cholesterol, fatty substances, cellular waste products, calcium and fibrin (a clotting material in the blood). Sometimes deposits in arteries are compared to a plumbing problem. This narrows the opening, reducing blood flow and the supply of oxygen to cells. Plaque may partially or totally block blood flow through a large or medium-sized artery in the heart, brain, pelvis, legs, arms or kidneys, further leading to various diseases. These include, coronary heart disease (plaque in arteries in or leading to the heart), angina (chest pain from reduced blood flow in arteries supplying the heart muscle), carotid artery disease (plaque in neck arteries that supply blood to the brain), peripheral artery disease (PAD; plaque in arteries of the extremities, especially the legs) and chronic kidney disease. Some of the drug candidates in the pipeline for treating arrhythmias include, but are not limited to, Immunitor, Plozalizumab and Canakinumab.
Some of the companies having drugs in the atherosclerosis pipeline include Humacyte, Inc., Unity Biotechnology, Inc., and Immusoft.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.